AMPK: An energy sensor for non-small cell lung cancer progression and treatment
Lung cancer (LC) is the leading cause of cancer-related morbidity and mortality in China, with non-small cell lung cancer (NSCLC) accounting for 85 % of the overall lung cancer cases. AMP-activated protein kinase (AMPK) is a key regulator of energy balance and homeostasis, and its dysregulation is a...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661825000179 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199558785761280 |
|---|---|
| author | Zhi-Ting Zhong Xu-Yan Wang Ying Pan Ke Zhou Jing-Hui Chen Yu-Qi Gao Bo Dai Zhi-Ling Zhou Rui-Qi Wang |
| author_facet | Zhi-Ting Zhong Xu-Yan Wang Ying Pan Ke Zhou Jing-Hui Chen Yu-Qi Gao Bo Dai Zhi-Ling Zhou Rui-Qi Wang |
| author_sort | Zhi-Ting Zhong |
| collection | DOAJ |
| description | Lung cancer (LC) is the leading cause of cancer-related morbidity and mortality in China, with non-small cell lung cancer (NSCLC) accounting for 85 % of the overall lung cancer cases. AMP-activated protein kinase (AMPK) is a key regulator of energy balance and homeostasis, and its dysregulation is a common feature in various malignancies, particularly in NSCLC with mutations in Liver kinase B1 (LKB1). Studies have shown that the AMPK signalling pathway has a dual role in NSCLC progression, both inhibiting and promoting the progression of malignant tumours. Therefore, drugs targeting the AMPK signalling pathway may hold significant promise for therapeutic application in NSCLC. This review aims to examine the manifestations and mechanisms by which AMPK and its associated signalling molecules influence NSCLC progression and treatment. Firstly, we discuss the critical importance of AMPK within the mutational context of NSCLC. Secondly, we summarise the drugs and related substances that modulate the AMPK signalling pathway in NSCLC and evaluate the evidence from preclinical studies on combination AMPK-targeted therapies to address the issue of drug resistance in NSCLC under current clinical treatments. In summary, this paper highlights the critical importance of developing AMPK-targeted drugs to enhance therapeutic efficacy in NSCLC, as well as the potential for applying these drugs in clinical therapy to overcome drug resistance. |
| format | Article |
| id | doaj-art-32b7a8809b6c4b92aaeaefb22377db38 |
| institution | Kabale University |
| issn | 1096-1186 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj-art-32b7a8809b6c4b92aaeaefb22377db382025-02-08T04:59:44ZengElsevierPharmacological Research1096-11862025-02-01212107592AMPK: An energy sensor for non-small cell lung cancer progression and treatmentZhi-Ting Zhong0Xu-Yan Wang1Ying Pan2Ke Zhou3Jing-Hui Chen4Yu-Qi Gao5Bo Dai6Zhi-Ling Zhou7Rui-Qi Wang8Department of Pharmacy, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, China; College of Pharmacy, Jinan University, Guangzhou, ChinaZhuhai Institute of Translational Medicine, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, ChinaDepartment of Oncology, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, ChinaDepartment of Pharmacy, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, ChinaDepartment of Pharmacy, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, ChinaDepartment of Pharmacy, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, ChinaDepartment of Cardiology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan City, Guangdong Province 528200, China; Corresponding authors.Department of Pharmacy, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, China; Corresponding authors.Department of Pharmacy, Zhuhai People’s Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, China; Corresponding authors.Lung cancer (LC) is the leading cause of cancer-related morbidity and mortality in China, with non-small cell lung cancer (NSCLC) accounting for 85 % of the overall lung cancer cases. AMP-activated protein kinase (AMPK) is a key regulator of energy balance and homeostasis, and its dysregulation is a common feature in various malignancies, particularly in NSCLC with mutations in Liver kinase B1 (LKB1). Studies have shown that the AMPK signalling pathway has a dual role in NSCLC progression, both inhibiting and promoting the progression of malignant tumours. Therefore, drugs targeting the AMPK signalling pathway may hold significant promise for therapeutic application in NSCLC. This review aims to examine the manifestations and mechanisms by which AMPK and its associated signalling molecules influence NSCLC progression and treatment. Firstly, we discuss the critical importance of AMPK within the mutational context of NSCLC. Secondly, we summarise the drugs and related substances that modulate the AMPK signalling pathway in NSCLC and evaluate the evidence from preclinical studies on combination AMPK-targeted therapies to address the issue of drug resistance in NSCLC under current clinical treatments. In summary, this paper highlights the critical importance of developing AMPK-targeted drugs to enhance therapeutic efficacy in NSCLC, as well as the potential for applying these drugs in clinical therapy to overcome drug resistance.http://www.sciencedirect.com/science/article/pii/S1043661825000179AMPKNSCLCLKB1mTOR |
| spellingShingle | Zhi-Ting Zhong Xu-Yan Wang Ying Pan Ke Zhou Jing-Hui Chen Yu-Qi Gao Bo Dai Zhi-Ling Zhou Rui-Qi Wang AMPK: An energy sensor for non-small cell lung cancer progression and treatment Pharmacological Research AMPK NSCLC LKB1 mTOR |
| title | AMPK: An energy sensor for non-small cell lung cancer progression and treatment |
| title_full | AMPK: An energy sensor for non-small cell lung cancer progression and treatment |
| title_fullStr | AMPK: An energy sensor for non-small cell lung cancer progression and treatment |
| title_full_unstemmed | AMPK: An energy sensor for non-small cell lung cancer progression and treatment |
| title_short | AMPK: An energy sensor for non-small cell lung cancer progression and treatment |
| title_sort | ampk an energy sensor for non small cell lung cancer progression and treatment |
| topic | AMPK NSCLC LKB1 mTOR |
| url | http://www.sciencedirect.com/science/article/pii/S1043661825000179 |
| work_keys_str_mv | AT zhitingzhong ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT xuyanwang ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT yingpan ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT kezhou ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT jinghuichen ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT yuqigao ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT bodai ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT zhilingzhou ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment AT ruiqiwang ampkanenergysensorfornonsmallcelllungcancerprogressionandtreatment |